Skip to content
Screener

Candel Therapeutics, Inc. CADL Prepaid & Other Current

Prepaid & Other Current at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.22B-22.8%
Amgen logo
AmgenAMGN
$4.53B+32.2%
Gilead Sciences logo
Gilead SciencesGILD
$3.76B+29.7%
Replimune Group logo
Replimune GroupREPL
$8.26M+3.6%
CG Oncology logo
CG OncologyCGON
$19.95M+74.7%
Regenxbio logo
RegenxbioRGNX
$11.9M+10.5%

Other financials

Income statement

See full
Revenue$31.0K0.0%
Operating income-$16.3M-100%
Net income-$8.9M-220%
EPS (diluted)-$0.14-208%

Balance sheet

See full
Cash & equivalents$194.8M+111%
Total debt$2.8M-73.9%
Total equity$138.0M+84.8%
Total assets$201.9M+111%

Cash flow

See full
Operating cash flow-$18.0M-109%
CapEx$675.0K+22,400%
Free cash flow-$18.7M-117%

Valuation

See full
Market cap$775.93M+157%
Enterprise value$583.94M+179%

Profitability

See full
Operating margin-28,000.8%+15,050pp
Net margin-15,156.5%-5,064pp
FCF margin-26,383.9%+14,851pp

Returns & leverage

See full
Return on equity-51.2%-16.6pp
Debt / equity-0.1×
Current ratio28×+23.4×

Where this comes from

Reported directly by Candel Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.

The source filing: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 8:30 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-222904
Line itemMARCH 31,2026(Unaudited)DECEMBER 31,2025
Assets
Current assets:
Cash and cash equivalents$194,834$119,731
Prepaid expenses and other current assets2,9181,658
Total current assets197,752121,389
Fixed assets, net2,0751,642
Lease right of use assets1,5691,661
Restricted cash416416

Item 1. Financial Statements.

FAQ

What is Candel Therapeutics, Inc.'s prepaid & other current?
Candel Therapeutics, Inc. (CADL) reported prepaid & other current of $2.92M in Q1 2026.
How has Candel Therapeutics, Inc.'s prepaid & other current changed year-over-year?
Candel Therapeutics, Inc.'s prepaid & other current increased by 196.8% year-over-year, from $983K to $2.92M.
What is the long-term trend for Candel Therapeutics, Inc.'s prepaid & other current?
Over 5 years (2020 to 2025), Candel Therapeutics, Inc.'s prepaid & other current has grown at a 77.9% compound annual growth rate (CAGR), from $93K to $1.66M.
What does prepaid & other current mean?
Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.

Ask your AI about Candel Therapeutics, Inc.'s prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude